Medlander (688273.SH) Launches A-Share Subscription at ¥40.29 per Share

According to the Zhisheng Finance APP, on August 2, Medlander (688273.SH) launched its subscription, with an issue price of 40.29 yuan per share, a subscription limit of 0.6 million shares, a price-to-earnings ratio of 38.51 times, belonging to the STAR Market, and Nanjing Securities as its exclusive sponsor.

Medlander mainly engages in the research, development, production, sales, and service of products related to pelvic floor and postpartum rehabilitation. The main products include pelvic floor and postpartum rehabilitation equipment, consumables and accessories, and information-based products, which are widely used in obstetrics and gynecology departments, women's health departments, gynecological departments, pelvic floor rehabilitation centers in medical institutions, as well as specialized institutions such as confinement centers, postpartum recovery centers, and maternal and child care centers. Based on years of industry experience, technical accumulation, abundant channel resources, and strong organizational capabilities in the field of pelvic floor and postpartum rehabilitation, the company actively expands into areas such as sports rehabilitation, female reproductive rehabilitation, nutrition, and health management. It has developed products like the Finger Joint Rehabilitation Assessment System, Electro-Ultrasound Therapy Device, Ultrasonic Uterine Involution Instrument, and Human Body Composition Health Management Analyzer, which will provide new momentum for the company’s continued rapid growth in future performance.

The company has gathered research and development personnel from multiple disciplines, including clinical medicine, computer software, and electronic information. It has also established good cooperative relationships with institutions such as Huazhong University of Science and Technology and Southeast University. During the reporting period, the company's R&D expenses were 25.42 million yuan, 41.35 million yuan, and 37.23 million yuan, respectively, accounting for 9.94%, 12.29%, and 10.90% of the revenue for the respective periods.

After the proceeds from this fundraising are in place, the Company will invest in the following projects in order of priority:

Financially, in 2019, 2020, and 2021, the company achieved operating revenues of approximately RMB 256 million, RMB 337 million, and RMB 342 million respectively, with net profits of approximately RMB 106 million, RMB 121 million, and RMB 120 million respectively.